Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2023 1
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study.
Pour L, Szarejko M, Bila J, Schjesvold FH, Spicka I, Maisnar V, Jurczyszyn A, Grudeva-Popova Z, Hájek R, Usenko G, Thuresson M, Norin S, Jarefors S, Bakker NA, Richardson PG, Mateos MV. Pour L, et al. Among authors: szarejko m. Haematologica. 2024 Mar 1;109(3):895-905. doi: 10.3324/haematol.2023.283509. Haematologica. 2024. PMID: 37646660 Free PMC article. Clinical Trial.
High Level of CD8+PD-1+ Cells in Patients with Chronic Myeloid Leukemia Who Experienced Loss of MMR after Imatinib Discontinuation.
Kwaśnik P, Zaleska J, Link-Lenczowska D, Zawada M, Wysogląd H, Ochrem B, Bober G, Wasilewska E, Hus I, Szarejko M, Prejzner W, Grzybowska-Izydorczyk O, Klonowska-Szymczyk A, Mędraś E, Kiełbus M, Sacha T, Giannopoulos K. Kwaśnik P, et al. Among authors: szarejko m. Cells. 2024 Apr 22;13(8):723. doi: 10.3390/cells13080723. Cells. 2024. PMID: 38667336 Free PMC article.
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib.
Machova Polakova K, Albeer A, Polivkova V, Krutska M, Vlcanova K, Curik N, Fabarius A, Klamova H, Spiess B, Waller CF, Brümmendorf TH, Dengler J, Kunzmann V, Burchert A, Belohlavkova P, Mustjoki S, Faber E, Mayer J, Zackova D, Panayiotidis P, Richter J, Hjorth-Hansen H, Kamińska M, Płonka M, Szczepanek E, Szarejko M, Bober G, Hus I, Grzybowska-Izydorczyk O, Wasilewska E, Paczkowska E, Niesiobędzka-Krężel J, Giannopoulos K, Mahon FX, Sacha T, Saußele S, Pfirrmann M. Machova Polakova K, et al. Among authors: szarejko m. Leukemia. 2024 Feb;38(2):318-325. doi: 10.1038/s41375-023-02109-2. Epub 2023 Dec 21. Leukemia. 2024. PMID: 38129513 Free PMC article.
A multicenter prospective study on efficacy and safety of imatinib generics: A report from Polish Adult Leukemia Group imatinib generics registry.
Sacha T, Góra-Tybor J, Szarejko M, Bober G, Grzybowska-Izydorczyk O, Niesiobędzka-Krężel J, Dudziński M, Wasilewska E, Myśliwiec K, Gil J, Gniot M, Pietkun I, Mędraś E, Hołojda J, Wącław J, Giannopoulos K. Sacha T, et al. Among authors: szarejko m. Am J Hematol. 2017 Jul;92(7):E125-E128. doi: 10.1002/ajh.24748. Epub 2017 May 26. Am J Hematol. 2017. PMID: 28376561 Free article. Clinical Trial. No abstract available.